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Abstract
Cancer antigen 15–3 (CA15-3) is widely utilized for monitoring metastatic breast cancer
(BC). However, its utility for early detection of breast cancer is severely limited due to poor
clinical sensitivity and specificity. The glycosylation of CA15-3 is known to be affected by BC,
and therefore it might offer a way to construct CA15-3 glycovariant assays with improved
cancer specificity. To this end, we performed lectin-based glycoprofiling of BC-associated
CA15-3. CA15-3 expressed by a BC cell line was immobilized on microtitration wells using an
anti-CA15-3 antibody. The glycosylation of the immobilized CA15-3 was then detected by
using lectins coated onto europium (III)-doped nanoparticles (Eu+3-NPs) and measuring the
time-resolved fluorescence of Eu. Out of multiple lectin-Eu+3-NP preparations, wheat germ
agglutinin (WGA) and macrophage galactose-type lectin (MGL) -Eu3+-NPs bound to the BC
cell line-dericed CA15-3 glycovariants (CA15-3Lectin). To evaluate the clinical performance of
these two lectin-based assays, plasma samples from metastatic BC patients (n = 53) and
healthy age-matched women (n = 20).Plasma CA15-3Lectin measurements better distin-
guished metastatic BC patients from healthy controls than the conventional CA15-3 immuno-
assay. At 90% specificity, the clinical sensitivity of the assays was 66.0, 67.9 and 81.1% for
the conventional CA15-3, CA15-3MGL and CA15-3WGA assays, respectively. Baseline CA15-
3MGL and CA15-3WGA were correlated to conventional baseline CA15-3 levels (r = 0.68,
p<0.001, r = 0.90, p>0.001, respectively). However, very low baseline CA15-3MGL levels� 5
U/mL were common in this metastatic breast cancer patient population.In conclusion, the
new CA15-3Lectin concept could considerably improve the clinical sensitivity of BC detection
compared to the conventional CA15-3 immunoassays and should be validated further on a
larger series of subjects with different cancer subtypes and stages.
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Introduction
Breast cancer (BC) is the most common cancer type and the second leading cause of cancer death
in women worldwide [1]. Cancer antigen 15–3 (CA15-3 also known as MUC1) is shed from
tumor cells and is a well-known serological marker for monitoring the clinical course of BC
patients. A persistent increase in circulating concentration of this marker may suggest an inade-
quate response to cancer therapy in patients with metastatic BC. However, it has poor sensitivity,
especially at early stages of the disease.[2] CA15-3 can also be elevated in healthy individuals and
in patients with benign conditions, and it lacks the specificity needed for cancer screening, diag-
nosis, staging, and/or sole use in monitoring of post-therapy recurrence [3]. A study on retrospec-
tive samples found the sensitivity of the commercial Elecsys CA 15–3 immunoassay to be 7, 11,
39 and 78% on stage I, II, III and IV BC patients, respectively [4]. Recently an ultrasensitive, sim-
ple and reliable electrochemical immunosensor was developed to detect the lowest alteration of
CA 15–3 and CA125, biomarker of breast and ovarian cancer patients respectively [5,6].
For monitoring metastatic breast cancer, international recommendations for the treatment
of metastatic BC only recommend the monitoring of CA15-3 levels for patients with non-
evaluable metastases, mainly bone-dominant disease [7,8]. Transient increases in plasma
CA15-3 levels are possible without tumor progression [9]. This phenomenon is observed espe-
cially in the beginning of chemotherapy due to necrosis and apoptosis of tumor cells. Addi-
tionally, consensus about clinically meaningful increase in plasma CA15-3 levels to predict
disease progression or clinically meaningful decrease to reflect a treatment response do not
exist today. Nevertheless, in general plasma CA15-3 levels correlate with the response to che-
motherapy in patients with metastatic breast cancer [10,11].
Protein glycosylation plays an important role in a wide variety of normal and disease-
related biological processes. The phenomenon of aberrant glycosylation associated with malig-
nant transformation, tumor progression and metastasis is well documented [12] and occurs in
essentially all types of human cancers. A large number of altered glycosyl epitopes are classified
as tumor-associated carbohydrate antigens. [13,14] Among these, the aberrant expression of
Tn and sialyl-Tn antigens, L-fucose and terminal N-acetylglucosamine (GlcNAc) have been
widely detected in breast cancers [15,16]. Especially, abnormal O-glycans, such as Tn antigen,
are found in over 90% of breast cancers[17]. Overall, changes in glycosylation result in the pro-
duction of various cancer-associated glycoproteins with cancer-associated glycoforms, which
are antigenically distinct from the corresponding molecules of the normal tissue. Taking into
account these modifications, the specificity of diagnostic cancer markers can be expected to be
improved by using the aberrant glycoforms as targets.
CA15-3 is upregulated and aberrantly glycosylated in breast and other carcinomas [18].The
CA15-3, derived from a large transmembrane protein Mucin 1 with molecular weight ranging
from 500 to 1000 kDa, contains multiple O- and N-linked glycosylation sites. The O-glycans of
CA15-3 produced by the normal breast tissue are core 2-based and can be complex, while the
O-glycans added to the BC mucin are mainly core 1-based [19]. The resulting truncated gly-
cans carried on BC-associated CA15-3 include Tn and T antigens and their sialylated forms
[14]. CA15-3 purified from the culture medium of human BC YMB-S cells contains 3-O-sul-
fated or 3-sialylated core 1 and extended core 1 glycans. [20]
Glycans participate in early stages of tumorigenesis [12] and it has been reported that the
expression level of an enzyme responsible for mucin-type glycosylation, N-acetylgalactosami-
nyltransferase-14, declines with breast cancer progression [21]. Thus, it is reasonable to
assume that the cancerous glycovariants of glycoprotein tumor markers appear early and differ
throughout the course of the disease. Therefore, glycovariant markers may be useful for early
detection as well as for monitoring cancer progression.
Breast cancer specific CA15-3 lectin assay
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Various lectins, members of a carbohydrate binding protein family, have previously been
used to investigate the differences in glycosylation between soluble glycoproteins expressed by
cancerous and benign tissues. A recent study described the use of a 3-sulfated core 1 -specific
galectin-4 (Gal-4) to establish an assay exhibiting superior clinical performance compared to
the conventional CA15-3 immunoassay for BC detection [22]. Also, C-type lectin receptors
(CLR) such as macrophage galactose-type lectin (MGL) have been demonstrated to show
increased binding to CA15-3 from lysates of colon cancer tissue compared to the healthy lysed
colon tissues of the same patients [23]. The Lens culinaris agglutinin, a lectin found in lentil, in
turn binds specifically to hepatocellular carcinoma -associated glycovariant of α-fetoprotein
(AFP) and is the only lectin used in a commercial application to detect a biomarker glycovar-
iant [24]. While showing these promising binding specificities, lectins unfortunately tend to
have weak binding affinity, which apparently limits their exploitation in practical assay
applications.
We previously reported a novel lectin-based approach for the detection of cancer-associated
glycosylation of CA125, a well-known mucin 16 -derived cancer marker used e.g. for monitor-
ing of epithelial ovarian cancer. The approach, relying on the use of highly fluorescent euro-
pium(III)-doped nanoparticles (Eu+3-NPs) coated with the lectin MGL, enabled highly
sensitive detection of CA125 produced by ovarian cancer cell line OVCAR-3. In the clinical
evaluation, the resulting optimized assay (CA125MGL) showed good discrimination between
the samples of epithelial ovarian cancer patients and those with endometriosis, a condition
that has decisively hampered the use of CA125 for early detection/screening of ovarian cancer.
[25] In addition, we found that the new assay could alarm clinicians much earlier (4–6
months) than the conventional CA125 assay about disease relapse. These results motivated us
to explore possibilities of the lectin nanoparticle assay concept for detecting the altered glyco-
sylation of CA15-3 in the blood streams of BC patients.
In the present work, we utilized the lectin-Eu+3-NP approach for the glycoprofiling of
CA15-3 with a panel of 28 lectins in order to identify lectins recognizing BC related changes in
carbohydrate structures of CA15-3. The discovered promising lectins were then validated with
plasma from patients with metastatic BC and healthy female controls. Additionally, we
explored new CA15-3lectin assays in monitoring response of metastatic breast cancer.
Materials and methods
Clinical samples
Plasma samples from 53 metastatic breast cancer patients were analyzed. These patients partic-
ipated in a first-line chemotherapy trial for metastatic breast cancer (NCT00979641). The sam-
ples were analyzed at baseline, after six weeks of chemotherapy treatment, after six months of
study treatment and at the final study visit. The trial design and the patient demographics have
been published previously [26]. In brief, the patients with metastatic HER2-negative BC were
enrolled into the trial, if they had not received previous chemotherapy for the advanced dis-
ease. The mean age of the study patients was 58 years (range 32–75). Most of the patients had
hormone receptor positive disease (81%) and visceral metastases (79%). The median time
between six-month sample and the final plasma sample was 11.8 months (inter quartile range
3.5.-18.9 months). The Ethics Committee of Tampere University Hospital approved the study
protocol (R08142M). Clinically meaningful change in CA15-3 levels was defined as 30% simi-
larly as the partial response criterion in the response evaluation criteria in solid tumors [27].
The definition of clinically meaningful change in circulating tumor markers varies around 20–
40% in previous studies [10,28]. Disease progression was defined as investigator-assessed
radiological progression according to the RECIST criteria [27].
Breast cancer specific CA15-3 lectin assay
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Control plasma samples were obtained from 20 healthy women participating in a mam-
mography-screening program in Tampere City Breast Clinic. These women voluntarily took
part in a breast cancer primary prevention study currently in progress at University of Tam-
pere and as a part of the study, plasma samples were drawn for scientific purposes. The mean
age of these healthy controls was 56 years (range 54–67). All participants gave written
informed consent (Ethics approval R15023).
Reagents
CA15-3 isolated from the breast cancer cell line ZR-75-1 (ATCC CRL-1500) (BC-CA15-3),
two monoclonal anti-CA15-3 antibodies; Ma552 and Ma695, that specifically recognize a
PDTRPAPG region of the protein core and sialylated carbohydrate epitope expressed on the
CA15-3 antigen respectively, were provided by Fujirebio Diagnostics (Go¨teborg, Sweden).
Streptavidin-coated yellow 96-well plates, wash buffer and red assay buffer were purchased
from Kaivogen (Turku, Finland). Europium(III)-doped Fluoro-Max polystyrene nanoparticles
(97 nm in diameter) (Eu+3-NP) were acquired from Seradyn (Indianapolis, IN, USA). A panel
of plant lectins with different glycan binding specificities (Table A in S1 Dataset) was obtained
from Vector laboratories (Burlingame, CA, USA). The recombinant human lectins were pur-
chased from R&D Systems (Abingdon, United Kingdom).
Preparation of lectin-Eu3+-NPs
The use of Eu+3-NPs has been described before [29]. The coating of lectins on Eu+3-NPs was
performed essentially as described before [30]. The buffer used for storage of the lectin coated
Eu+3-NPs was 10 mM Tris-HCl, pH 7.8, supplemented with 0.1% BSA and 0.01% sodium
azide at +4˚C, covered from light. The particles were thoroughly vortexed and sonicated before
every use to disperse aggregates.
Labelling of antibodies with biotin
Both solid-phase monoclonal antibodies (Ma552 and Ma695 mAb) were biotinylated with
40-fold molar excess of biotin isothiocyanate, for 4 h at room temperature (RT). The labelled
antibodies were separated from the unconjugated biotin by using NAP-5 and NAP-10 gel-fil-
tration columns (GE Healthcare, Schenectady, NY, USA) by using 50 mM Tris–HCl (pH
7.75), containing 150 mM NaCl and 0.5 g/L NaN3. The labelled antibodies were stabilized
with 1 g/L BSA (Bioreba, Nyon, Switzerland) and stored at +4˚C. [31]
In-house CA15-3 Lectin-NP assay
The assay principle is represented in Fig 1. Biotinylated Ma552 or Ma695 mAb (100 ng/30 μl/
well) in buffer solution was incubated for 1 h at RT to immobilize them on streptavidin-coated
yellow low-fluorescence microtiter wells. The wells were washed two times with wash buffer
and 25 μl of CA15-3 standard/sample (diluted 1:40 in buffer) was added and incubated for 1 h
at RT with slow shaking. The immobilized BC-CA15-3 was detected by lectin-Eu3+-NPs as a
tracer by using time-resolved fluorescence (TRF). Ten million lectin Eu+3 -NPs per well in
25 μl of assay buffer containing additional 6 mM CaCl2 was added. The wells were incubated
for two hours at RT in shaking and washed six times. To detect the lectin-Eu3+-NPs bound to
BC-CA15-3, the TRF of Eu (λex: 340 nm; λem: 615 nm) was measured for 400 μs after a 400 μs
delay using Victor3V 1420 Multilabel counter (Wallac, Turku, Finland).
Breast cancer specific CA15-3 lectin assay
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Conventional CA15-3 immunoassay
CA15-3 concentrations were analysed in plasma samples with a CA15-3 enzyme immunoassay
(Fujirebio Diagnostics Inc., Malvern, PA, USA) according to manufacturer’s instructions.
Statistical analysis
Receiver operating characteristics (ROC) were determined and compared, and the areas under
the curve (AUC) values calculated using R version 3.3. [32] with the pROC package [33]. The
measured concentrations of each assay (Table B in S1 Dataset) were used as the classifier. The
comparison of ROCs was done using the bootstrap method provided in the pROC package. Due
to the nonparametric distribution of the CA15-3 levels, medians with the interquartile range
(IQR) of the median were reported. CA15-3 levels of healthy controls were compared to CA15-3
levels of metastatic BC patients using the Mann Whitney U-test. Wilcoxon Rank test was used
when comparing baseline and week six CA15-3 levels in relation to the treatment response.
Spearman’s correlation was used to study the correlation between conventional CA15-3 levels
and CA15-3MGL or CA15-3WGA levels. The Wilcoxon signed-rank test and Spearman’s correla-
tion analyses were performed using SPSS version 23 statistical software package (SPSS Inc., Chi-
cago, IL, USA). P value of less than 0.05 was considered significant in all statistical tests.
Results
Screening of lectins for binding to BC-CA15-3
Altogether 28 lectins with various carbohydrate-binding specificities (Table A in S1 Dataset)
were tested to investigate the glycosylation patterns of the cancer cell line -derived BC-CA15-3
Fig 1. The principle of the conventional and in-house Eu+3-NP-based CA15-3 lectin assays. In the conventional CA15-3 immunoassay, the capture and tracer mAbs
bind to the protein and glycan epitopes of CA15-3. Alternatively, in the lectin assay, the CA15-3 is captured with mAbs and detected with lectins, which have been coated
on the surface of Eu3+-NPs. This method allows multivalent binding of the tracer to the glycan moieties of BC-CA15-3.
https://doi.org/10.1371/journal.pone.0219480.g001
Breast cancer specific CA15-3 lectin assay
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preparation. Fig 2 shows the signal-to-background ratios obtained with the corresponding lec-
tin-NP tracers using two different monoclonal antibodies (Ma552 and Ma695) for capturing
CA15-3. Four of the tested nanoparticle tracers; MGL- WGA-, Gal-4-, and DSL-NPs, recog-
nized BC-CA15-3 and the trend was similar for both capture antibodies. WGA exhibited high-
est signal-to-background ratio followed by MGL, Gal-4 and DSL (Fig 2). WGA- and
MGL-NPs displayed excellent recovery (93% to 98%) when BC-CA15-3 was spiked into pooled
healthy plasma samples whereas Gal-4- and DSL-NPs scarcely bound to BC-CA15-3 spiked
Fig 2. Lectin NPs binding to BC-associated CA15-3 from cell line ZR-75-1 (ATCC CRL-1500) using the lectin assay principle depicted in Fig 1.
The different lectin Eu+3-NPs used are shown on the x-axis and the y-axis displays the signal to background ratios using either biotinylated Ma695
(bioMa695) or biotinylated Ma552 (bioMa552) as the capture mAb.
https://doi.org/10.1371/journal.pone.0219480.g002
Breast cancer specific CA15-3 lectin assay
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similarly in plasma. We selected MGL (here after, CA15-3MGL) and WGA (CA15-3WGA) for
further evaluation using clinical samples.
Characteristics of CA15-3MGL CA15-3WGA assays
The analytical performance of the CA15-3MGL and CA15-3WGA assays were preliminarily
tested using a BC-CA15-3 in a range of concentrations from 1 to 1000 U/mL. Saturation
was not observed at the maximum used BC-CA15-3 of 1000 U/mL. The limit of detection,
which was set to be the concentration of BC-CA15-3 required for a signal equivalent to the
mean of blank calibrator (n = 20) plus three times the standard deviation, was less than 1 U/
mL. Linear in response was observed at a maximum of 125 U/mL (S1 Fig). No cross-reactiv-
ity was observed towards two other glycoprotein cancer markers, CA125 and prostate spe-
cific antigen (S2 Fig).
Plasma CA15-3, CA15-3MGL, and CA15-3WGA concentrations in the study
cohort
We next studied whether CA15-3 in the plasma of BC patients binds with MGL and WGA
similar to CA15-3 of a breast cancer cell line. The baseline EDTA plasma samples from 53
patients with metastatic BC and 20 healthy individuals were measured for CA15-3MGL and
CA15-3WGA and compared with the conventional CA15-3 immunoassay. To assess the diag-
nostic value of the tumor markers in metastatic BC, ROC curves were plotted and AUC was
calculated. The highest AUC value was achieved with CA15-3WGA (0.943) followed by CA15-
3MGL (0.852) while the conventional CA15-3 immunoassay yielded the lowest AUC of 0.827
(Fig 3). At 90% specificity the sensitivities of the assays were 81.1, 67.9 and 66.0% for the
CA15-3 WGA, CA15-3MGL and conventional CA15-3, respectively. The difference in the AUC
compared to the conventional assay was significant for CA15-3WGA (p = 0.007) but not for
CA15-3MGL (p = 0.655).
Metastatic BC patients had higher median baseline plasma levels of conventional CA15-3 as
well as CA15-3MGL and CA15-3WGA levels than the healthy controls (Table 1). Plasma samples
were available from 53 metastatic breast cancer patients. However, both baseline and week six
samples were available only from 41 patients. Median CA15-3 levels were lower at week six
than at baseline for all three CA15-3 assays in the entire study population (p-values 0.007,
<0.001, <0.001 for CA15-3, CA15-3MGL and CA15-3WGA, respectively). The decline in CA15-
3 levels was more pronounced in responding patients for all CA15-3 assays, especially CA15-
3MGL (Table 2). For all the three different CA15-3 assays, the responding patients had a signifi-
cant decrease in all assays of CA15-3 between baseline and week six (p-values 0.003, <0.001
and<0.001 for CA 15–3, CA15-3MGL and CA15-3WGA, respectively, Table 2).
Baseline conventional CA15-3 and CA15-3MGL levels correlated to each other (r = 0.68,
p<0.001, Fig 4A and 4B). However, almost half of the metastatic BC patients had very low
baseline CA15-3MGL levels (� 5 U/Ml, dashed vertical line in Fig 4B). A stronger correlation
was observed between conventional CA15-3 and CA15-3WGA (r = 0.90, p<0.001, Fig 4C
and 4D).
Additionally, we studied CA15-3 levels at disease progression (Fig 5).We had plasma sam-
ples available from 19 patients who had a disease progression at final study visit. A clinically
meaningful 30% increase in the final CA15-3 levels was observed in eight patients (42%) with
the conventional CA15-3, nine patients (47%) with the CA15-3MGL and six patients (32%)
with the CA15-3WGA. The patients with rising CA15-3 levels at disease progression were not
entirely the same individuals for the different CA15-3 assays. Specifically, five patients had
similar increase in final CA15-3MGL levels and CA15-3 levels. However, four patients with
Breast cancer specific CA15-3 lectin assay
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rising CA15-3MGL levels did not have an increase in conventional CA15-3 levels. Furthermore,
a similar increase was observed in four patients in final CA15-3WGA and conventional CA15-3
levels. However, two patients with rising CA15-3WGA levels did not have an increase in con-
ventional CA15-3 levels. Additionally, at least 30% decrease in the final CA15-3 levels at dis-
ease progression was observed in three patients (16%) with the conventional CA15-3, 3
patients (16%) with CA15-3MGL and five patients (26%) with CA15-3WGA.
Fig 3. ROC plot displaying the AUC of conventional CA15-3 (green), CA15-3MGL (purple) and CA15-3WGA (red) from metastatic
breast cancer patients (n = 53) and healthy control (n = 20). The 95% confidence intervals of the ROCs are depicted as shaded areas and
displayed numerically in brackets. The color of shadings corresponds to the plotted lines and the overlap of conventional CA15-3 and CA15-
3MGL is dark green, the overlap of all assays is brown and the overlap of CA15-3MGL and CA15-3WGA is dark red.
https://doi.org/10.1371/journal.pone.0219480.g003
Breast cancer specific CA15-3 lectin assay
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Discussion
The results suggest that the glycovariant specific assays provide advantages over the conven-
tional CA15-3 immunoassay in monitoring of BC patients, and especially for the detection of
metastatic disease and its recurrence.
CA15-3 is a tumor marker commonly used for monitoring patients with advanced BC.
However, the currently employed sandwich immunoassays that target two protein epitopes
have moderate clinical sensitivity and specificity. [34] While it has been established that abnor-
mal glycosylation occurs in cancers and there has been investigations into multiple different
approaches for their detection [35] the efforts to further develop the CA15-3 based diagnostic
assay have been limited. The changes in glycosylation can lead to altered interactions of glyco-
proteins expressed by the tumor cell with different lectins. The development of glycoprofiling
assays for blood-derived products has been made difficult by the fact that cancer specific gly-
covariants may only exist in small amounts in blood and are therefore problematic to detect.
We have previously utilized the lectin-NP -based platform successfully to explore the
Table 1. CA15-3 levels by conventional CA15-3, CA15-3MGL, and CA15-3WGA assay for healthy controls and for metastatic BC patients at study baseline.
n Conventional CA15-3 CA15-3MGL CA15-3WGA
Healthy controls
Median CA15-3 U/mL (IQR) 20 13.3 (7.9–23.1) 2.0 (0.2–3.6) 1.6 (0.5–2.7)
Metastastic BC patients, Baseline
Median CA15-3 U/mL (IQR) 53 47.4 (18.9–99.9) 4.4 (1.3–16.5) 7.0 (3.1–41.0)
p-valuea <0.001 0.013 <0.001
Abbreviations: n = number of patients, IQR = interquartile range, BC = breast cancer
a Mann-Whitney U-test
https://doi.org/10.1371/journal.pone.0219480.t001
Table 2. CA15-3 levels with different assays depending on the best response to the chemotherapy treatment.
n Baseline
Median CA15-3, U/mL
(IQR)
Week 6
Median CA15-3 U/mL
(IQR)
Change, median %
(IQR)a
pb Declining CA15-3 levels, n
(%)c
Increase in CA15-3 levels, n
(%)d
Conventional CA15-3
PR 25 71.1 (29.4–228) 55.4 (28.8–103) -23.8 [-52.7-(-14.0)] 0.003 10 (40.0) 2 (8.0)
SD 14 19.2 (12.6–81.4) 25.8 (14.9–71.0) -0.4 (-37.1–60.5) 0.875 4 (28.6) 5 (35.7)
PD 2 24.1 (15.0–33.1) 29.2 (17.5–40.9) +20.1 (16.7–23.6) 0.180 0 0
CA15-3MGL
PR 25 6.3 (2.1–45.1) 2.4 (0.9–4.8) -75.0 [-86.4-(-41.0)] <0.001 18 (78.2) 3 (13.0)
SD 14 3.2 (1.0–5.4) 2.2 (0.8–3.6) -33.3 (-67.0–33.3) 0.036 7 (53.8) 4 (30.7)
PD 2 4.1 (3.2–5.0) 3.0 (2.2–3.9) -17.0 (-56.0–21.9) 0.655 1 (50.0) 0
CA15-3WGA
PR 25 13.2 (5.3–76.5) 8.0 (3.5–33.2) -27.2 [-55.9-(-19.4)] <0.001 12 (48.0) 2 (8.0)
SD 14 3.2 (2.4–8.7) 5.0 (2.7–8.2) +22.2 (-25.4–60.0) 0.851 3 (21.4) 7 (50.0)
PD 2 4.7 (2.3–7.0) 5.8 (2.3–9.3) +16.4 (0–32.9) 0.317 0 1 (50.0)
Abbreviations: n = number of patients, CI = confidence interval, PR = partial response, SD = stable disease, PD = progressive disease
a Change in CA15-3 levels from baseline to week six in percentiles, median
b Wilcoxon Rank Test
c Patients with� 30% decline in CA15-3 levels from baseline to week six
d Patients with� 30% increase in CA15-3 levels from baseline to week six
https://doi.org/10.1371/journal.pone.0219480.t002
Breast cancer specific CA15-3 lectin assay
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glycosylation of serum glycoprotein CA125 in ovarian cancer patients [25]. Two features in a
combination enhance the analytical sensitivity of lectin-NPs; 1) signal amplification provided
by the thousands of Eu chelates doped in a single particle and 2) the strengthening of the func-
tional affinity (avidity) of the lectins to their target glycostructure epitopes enabled by the
high-density immobilization of lectin on the particles.
The present study shows for the first time that a qualitative glycovariant assay to detect the
changes of the CA15-3 glycoprotein can improve on the diagnostic utility of current assays.
We developed an assay for sensitive and quantitative detection of aberrant glycosylation on
BC-CA15-3 providing enhanced preference for the cancer-associated glycovariant of the
tumor marker. An antibody recognizing the protein/glycan epitopes of CA15-3 was used for
Fig 4. Correlation of the conventional CA15-3 and CA15-3Lectin assays. A: Scatterplot of baseline conventional CA15-3 levels and baseline CA15-3MGL levels in
metastatic breast cancer patients. r = 0.68, p<0.001 B: Enlargement of the scatterplot for the patients with the lowest CA15-3 levels for both conventional CA15-3
and CA15-3MGL. Very low baseline CA15-3MGL levels< 5 U/mL were observed in 29 patients (44.6%), dashed vertical line at x-axis C: Scatterplot of baseline
conventional CA15-3 levels and baseline CA15-3WGA levels in metastatic breast cancer patients. r = 0.90, p<0.001. D: Enlargement of the scatterplot for the patients
with conventional CA15-3< 250 U/mL and CA15-3WGA< 130 U/mL, 85% of the study patients.
https://doi.org/10.1371/journal.pone.0219480.g004
Breast cancer specific CA15-3 lectin assay
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the immobilization and a panel of lectins was tested for the ability to bind the immobilized
CA15-3. The tested panel of 28 lectins covers a variety of common human glycans. Only two
of the tested lectin-Eu+3-NP preparations exhibited satisfactory binding to the BC-associated
CA15-3. Those lectins were WGA and recombinant human MGL. WGA and MGL recognize
the GlcNAc and GalNAc -containing epitopes respectively, frequently expressed on the surface
of cancer cells [36–38]. Using CA15-3WGA and CA15-3MGL assays, in the plasma of metastatic
BC patients are likely to serve as more cancer-specific than the conventional assay. In patients
with metastatic BC, the newly developed CA15-3WGA assay was able to detect 81% compared
to 66% with conventional CA15-3 assay when only 10% of controls were misdiagnosed with
both assays.
Consistent with these findings, Nollau P et al. describe the use of recombinant MGL (also
known as CLEC10A), for the detection of ligands in sections from formalin-fixed, paraffin-
embedded normal and cancerous mammary tissues. In comparison to normal mammary
glands, a pronounced staining of tumour tissues was observed. [37] Beatson R et al. also
observed that MUC1 carrying both Tn and STn epitopes can bind to the human lectin MGL,
and using atomic force microscopy they showed that Tn and sTn bind to MGL with a similar
de-adhesion force. [39] Our study reports the binding of that same human lectin MGL with
plasma of BC patients and particularly with CA15-3. Blixt et al. reported that high levels of a
subset of autoantibodies to the core 3-MUC1 (GlcNAcβ1-3GalNAc-MUC1) and STn-MUC1
glycoforms were significantly associated with reduced incidence and increased time to metas-
tasis, which also supports our findings of MGL binding [18].
As far as we know, this study is the first to report WGA’s specificity for BC-CA15-3. WGA
is a plant lectin, which specifically recognizes the sugars NeuNAc and GlcNAc [39]. It has been
reported that terminal GlcNAc is characteristic of a group of protein- and lipid-linked glycans
overexpressed in many malignant tumor tissues including breast carcinoma [16].
Fig 5. CA15-3 levels of 19 patients who had a disease progression at the time of final plasma sampling and a previous reference plasma available
while on study treatment (Reference). A. Conventional CA15-3. Two patients with very high CA15-3 levels were excluded (Reference CA15-3 110.6 U/
mL, Final 986.4 U/mL and Reference 1825.5 U/mL, Final 3909.7 U/mL) B. CA15-3MGL. C. CA15-3WGA. One patient with very high CA15-3WGA level
was excluded (Reference CA15-3WGA 393.1 U/mL, Final CA15-3WGA 430.9 U/mL).
https://doi.org/10.1371/journal.pone.0219480.g005
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Chandrasekaran EV et al studied the complex carbohydrate-lectin interactions by determining
the effects of substituents in mucin core 2 tetrasaccharide Galβ1-4GlcNAcβ1-6(Galβ1–3) Gal-
NAcα-OR and fetuin glycopeptides on their binding to agarose immobilized lectin WGA.
Compounds with α2-3-sialyl T-hapten, α2-6-Sialyl LacdiNAc, α2-3-sialyl D-Fucβ1–3 GalNAc
and Fucα-1-2 D-Fucβ-1-3GalNAc displayed regular binding and GalNAc, LewisX and Lacdi-
NAc plus D-Fuc β-1-3 GalNAcα exhibited particularly tight binding.[40] A previous study by
Bird-Liebermann EL et al identified GlcNAc as a biomarker for endoscopic visualization of
Barrett’s esophagus to detect dysplastic esophageal tissue [41]. Using a serum CA15-3 lectin
assay based on antibody-capture, Ideo et al. showed that 3-sulfated core 1 specific Gal-4 can be
used to measure CA15-3 that is present in BC[22]. We observed in our study that Gal-4 bound
more poorly to BC-CA15-3 than MGL and WGA.
The specificity provided by the immobilizing antibody together with the glycan-recognition
of the lectins, which is enhanced through the avidity made possible by the Eu+3-NPs, consti-
tute the technical concept behind the novel CA15-3MGL and CA15-3WGA assays. These assay
strongly prefer the cancer-associated glycovariants compared to conventional CA15-3 sand-
wich immunoassay. Based on previously published research on the nature of CA15-3 glycosyl-
ation in malignant and benign states, the WGA preference for cancer CA15-3 would have
been difficult to predict. It is possible that the glycan eiptopes reactive with MGL and WGA
are be present on several CA15-3 glycans, being a sizable 500–1000 kDa glycoprotein. The
extracellular domain of CA15-3 consists mainly of 25–150 tandem repeats of 20 amino acids.
Each repeat carries five O-linked glycosylation sites, thus glycans can potentially be repeated
125–750 times on each molecule allowing engagement of relevant lectins.[20] The high
amount of glycans makes the presence of multiple binding sites for MGL and WGA Eu+3-NPs
plausible and may provide for high avidity even at low CA15-3 concentration. The low limit of
detection and great linearity of the standard in the range of 1-100 U/ml of analyte agrees with
this assessment.
The monitoring of conventional CA15-3 levels for therapy response of metastatic BC is cur-
rently recommended only as an adjunctive assessment to aid clinical decisions[42].This is
mostly due to low sensitivity and specificity of the conventional CA15-3 assay. Additionally,
the conventional CA15-3 levels may have discrepancies compared to clinical findings and
radiological assessments[10]. Although for majority of patients, the tumor markers decline in
responding patients and increase in progressing patients, misinterpretations are possible if
tumor markers are evaluated alone for an individual patient. In our study, 10 patients (40%)
with a partial response to study treatment had at least 30% decline in conventional CA15-3 lev-
els between baseline and week six. However, declining plasma levels for responding patients
were more common both with the CA15-3MGL method (18 patients, 78%) and the CA15-3WGA
method (12 patients, 48%). Therefore, new CA15-3lectin assays recognize the responding
patients better than the conventional CA15-3. False positive increases in CA15-3 levels were
observed for responding patients for all three assays between baseline and week six (two
patients for conventional CA15-3 and CA15-3WGA, three patients for CA15-3MGL). At the
time of progressive disease, only minority of patients had over 30% increase in their CA15-3
levels [conventional CA15-3 assay 8 patients (42%), CA15-3MGL 9 patients (47%), CA15-3WGA
5 patients (26%)].
Comparing the new lectin assays to one another, CA15-3WGA seems to be more suitable for
clinical use than CA15-3MGL. The clinical utility for CA15-3MGL levels is limited due to very
low< 5 IU/mL baseline levels detected for almost half of our study patients. Additionally, the
correlation between conventional CA15-3 and CA15-3WGA was more pronounced (r = 0.90,
p<0.001). Nevertheless, for this limited patient population, CA15-3MGL and CA15-3WGA seem
not yet to be ideal assays for clinical utility and the possibilities for misinterpretations for an
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individual patient remains as it does for the conventional CA15-3 assay. However, it would be
worthwhile test these CA15-3lectin assays in a prospective trial involving metastatic breast can-
cer patients.
This study suggests that using CA15-3 mAb and WGA and MGL Eu3+NPs are more sensi-
tive in distinguishing metastatic BC patients from healthy controls than conventional CA15-3
immunoassay.
Due to the limited amount of patient samples used in this proof of concept study report,
studies for further validation, to establish the clinical performance of CA15-3WGA and CA15-
3MGL assays for BC surveillance, and monitoring progression and therapeutic responses of
metastatic disease, are now under investigation. The findings also warrant further investigation
of this approach in other cancers.
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